BC002230 Inhibitors
Chemical inhibitors of BC002230 can modulate the protein's activity through a variety of molecular mechanisms. Staurosporine is a broad-spectrum protein kinase inhibitor that can inhibit BC002230 by blocking its phosphorylation, which is a crucial post-translational modification for the activity of many proteins. Similarly, PD98059 and U0126, both selective inhibitors of MEK, can disrupt the MAPK/ERK pathway, leading to reduced phosphorylation and subsequent activity of BC002230 if it is part of this signaling cascade. LY294002 and Wortmannin, as PI3K inhibitors, can diminish the PI3K/Akt pathway signaling, which may be necessary for the activation of BC002230 or proteins that regulate its function. SP600125, targeting the JNK signaling pathway, can alter the phosphorylation state of proteins that interact with BC002230, potentially leading to changes in its activity.
Moreover, SB203580 inhibits p38 MAPK, a kinase that responds to stress signals, which could lead to the inhibition of BC002230 if its function is associated with this pathway. Bortezomib, a proteasome inhibitor, can alter the degradation or stability of BC002230 or its regulatory proteins, impacting its activity. AG-490 targets JAK2 kinase within the JAK/STAT signaling pathway, which can affect BC002230 activity through the phosphorylation and activation of STAT proteins. Sotrastaurin, a selective inhibitor of protein kinase C (PKC), can also modulate the activity of BC002230 by altering PKC-mediated phosphorylation events. Lastly, ZM-447439, an Aurora kinase inhibitor, can disrupt cell cycle progression and chromosomal segregation, which could affect the function of BC002230 if it is involved in these processes. Each of these inhibitors targets specific molecular pathways and can modulate the activity of BC002230 by influencing the phosphorylation status and the signaling pathways that it is associated with.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. If BC002230 is a protein kinase or is regulated by kinase activity, staurosporine can inhibit BC002230 by preventing its phosphorylation or the phosphorylation of proteins that directly regulate BC002230's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cell growth and proliferation. By inhibiting this pathway, rapamycin can decrease the activity of downstream proteins regulated by mTOR that may be essential for the function of BC002230, thereby functionally inhibiting BC002230. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. If BC002230's function is related to this pathway, PD98059 can inhibit the phosphorylation of ERK, potentially leading to a functional inhibition of BC002230 if its activity is dependent on the MAPK/ERK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, this compound can lead to a functional reduction in the PI3K/Akt pathway signaling, which, if BC002230's activity is PI3K/Akt-dependent, would result in the functional inhibition of BC002230 by blocking its activation or the activation of associated proteins. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and it operates in a similar manner to LY294002. If BC002230 relies on PI3K signaling, wortmannin can inhibit this pathway, leading to a decrease in BC002230's activity by preventing its necessary activation or the activation of proteins that control BC002230's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK is involved in stress and apoptosis signaling pathways. Inhibition of JNK can lead to the functional inhibition of BC002230 if it is regulated by or involved in the JNK signaling pathway by altering the phosphorylation state of proteins that interact with BC002230. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a protein involved in response to stress and cytokines. If BC002230's activity is tied to p38 MAPK signaling, inhibiting this kinase can prevent the functional activity of BC002230 by disrupting the signaling cascade that it is a part of. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK, similar to PD98059. It can functionally inhibit BC002230 by blocking the MAPK/ERK pathway. If BC002230 operates within this pathway, the inhibition of MEK can prevent the activation or the activity of BC002230 by altering the phosphorylation of associated proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If BC002230 is regulated through proteasomal degradation or interacts with proteins that are, bortezomib can lead to the accumulation of such regulatory proteins, which might inhibit the function of BC002230 by altering its degradation or stability. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490 is a JAK2 inhibitor. If BC002230 is part of the JAK/STAT signaling pathway, inhibition of JAK2 by AG-490 can functionally inhibit the activity of BC002230 by preventing the phosphorylation and activation of STAT proteins that may regulate BC002230. | ||||||